Robert Gould, Fulcrum Therapeutics CEO
August 11, 2020 10:37 AM EDTUpdated 03:45 PM
R&D

Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

Jason Mast

Editor

In­vestors are sell­ing off shares of Ful­crum Ther­a­peu­tics $FULC af­ter their lead drug failed in a Phase II tri­al.

The com­pa­ny, found­ed three years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times